engleski

Tigecycline, a New Therapeutic Option

Tigecycline is a new antbiotic active against gram-positive bacteria, particularly MRSA, and some gram-negative bacteria (not Pseudomonas). This is its main advantage over other new antibiotics which are almost all effective against gram-positives. Tigecycline is a broad-spectrum glycylcycline antibiotic that is related in structure to minocycline. It is only available for intravenous infusion. Until now it is approved for the treatment of complicated skin and soft tissue infections and intraabdominal infections. Recruitment of patients in the 3rd phase of clinical trial of community acquired pneumonia finished. Soon we can expect results. In that trial tigecycline was compared to levofloxacin. Clinical trial on its use in nosocomial and nosohuisal pneumonia is ongoing. Nosocomial infections are indication where we have highest expectations – it offer some advanteges over vancomycin (less toxicity, activity against some important gram-negative bacteria including Acinetobacter, linezolid (less thrombocytopenia, drug fever, optic nerve toxicity) but more nausea and vomiting, daptomycin which can not be used in the treatment of pneumonia. Even present limited experience with tigecycline shows that we have a promising agent in our armatory against MRSA and other nosocomial pathogens.

tigecyclyne

nije evidentirano